The Future of Glioblastoma Therapy: Synergism of Standard of Care and Immunotherapy

Cancers

Mira A. Patel¹  Jennifer E. Kim¹  Jacob Ruzevick¹  Gordon Li² 

[1] Department of Neurosurgery, The Johns Hopkins University School of Medicine, 600 N. Wolfe St., Phipps Building Rm 123, Baltimore, MD 21287, USA; E-Mails:;Department of Neurosurgery, Stanford University Medical Center, 1201 Welch Rd., P309 MSLS, Stanford, CA 94305, USA; E-Mail:

关键词: glioblastoma;    temozolomide;    vaccine;    immunotherapy;   

DOI  :  10.3390/cancers6041953

来源: mdpi

【 摘 要 】

The current standard of care for glioblastoma (GBM) is maximal surgical resection with adjuvant radiotherapy and temozolomide (TMZ). As the 5-year survival with GBM remains at a dismal <10%, novel therapies are needed. Immunotherapies such as the dendritic cell (DC) vaccine, heat shock protein vaccines, and epidermal growth factor receptor (EGFRvIII) vaccines have shown encouraging results in clinical trials, and have demonstrated synergistic effects with conventional therapeutics resulting in ongoing phase III trials. Chemoradiation has been shown to have synergistic effects when used in combination with immunotherapy. Cytotoxic ionizing radiation is known to trigger pro-inflammatory signaling cascades and immune activation secondary to cell death, which can then be exploited by immunotherapies. The future of GBM therapeutics will involve finding the place for immunotherapy in the current treatment regimen with a focus on developing strategies. Here, we review current GBM therapy and the evidence for combination of immune checkpoint inhibitors, DC and peptide vaccines with the current standard of care.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.